1. Home
  2. FATN vs KLRS Comparison

FATN vs KLRS Comparison

Compare FATN & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FATN
  • KLRS
  • Stock Information
  • Founded
  • FATN 1989
  • KLRS 2019
  • Country
  • FATN United States
  • KLRS United States
  • Employees
  • FATN N/A
  • KLRS N/A
  • Industry
  • FATN
  • KLRS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FATN
  • KLRS Health Care
  • Exchange
  • FATN NYSE
  • KLRS Nasdaq
  • Market Cap
  • FATN 111.3M
  • KLRS 129.0M
  • IPO Year
  • FATN 2025
  • KLRS N/A
  • Fundamental
  • Price
  • FATN $7.13
  • KLRS $3.48
  • Analyst Decision
  • FATN
  • KLRS Buy
  • Analyst Count
  • FATN 0
  • KLRS 1
  • Target Price
  • FATN N/A
  • KLRS N/A
  • AVG Volume (30 Days)
  • FATN 815.7K
  • KLRS 62.3K
  • Earning Date
  • FATN 01-01-0001
  • KLRS 05-19-2025
  • Dividend Yield
  • FATN N/A
  • KLRS N/A
  • EPS Growth
  • FATN 56.77
  • KLRS N/A
  • EPS
  • FATN 0.37
  • KLRS N/A
  • Revenue
  • FATN $17,876,645.00
  • KLRS N/A
  • Revenue This Year
  • FATN N/A
  • KLRS N/A
  • Revenue Next Year
  • FATN N/A
  • KLRS N/A
  • P/E Ratio
  • FATN $19.69
  • KLRS N/A
  • Revenue Growth
  • FATN 13.17
  • KLRS N/A
  • 52 Week Low
  • FATN $5.60
  • KLRS $4.19
  • 52 Week High
  • FATN $23.27
  • KLRS $24.15
  • Technical
  • Relative Strength Index (RSI)
  • FATN N/A
  • KLRS N/A
  • Support Level
  • FATN N/A
  • KLRS N/A
  • Resistance Level
  • FATN N/A
  • KLRS N/A
  • Average True Range (ATR)
  • FATN 0.00
  • KLRS 0.00
  • MACD
  • FATN 0.00
  • KLRS 0.00
  • Stochastic Oscillator
  • FATN 0.00
  • KLRS 0.00

About FATN FATPIPE INC

Fatpipe Inc is a pioneer in enterprise-class, application-aware, secure SD-WAN solutions for organizations, including enterprises, communication service providers, security service providers, government organizations, and other middle-market companies. It is engaged in delivering principal enterprise-class networking software technology. The company is dedicated to continually improving the way organizations connect, ensuring their networks are secure, reliable, and supporting their continued success. Its commitment lies in empowering its customers with a seamless and dependable connectivity infrastructure that safeguards their critical data and fosters business continuity. Further, the company's goal is to ensure its customers have unparalleled insights into their network operations.

About KLRS Kalaris Therapeutics Inc. Common Stock

Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.

Share on Social Networks: